Article
Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
Blood - 5 Nov 2020
Xiao Yanling, van Halteren Astrid G S, Lei Xin, Borst Jelske, Steenwijk Eline, de Wit Tom, Grabowska Joanna, Voogd Rhianne, Kemps Paul, Picarsic Jennifer, van den Bos Cor, Borst Jannie
Abstract excerpt
Langerhans cell histiocytosis (LCH) is a myeloid neoplasia, driven by sporadic activating mutations in the MAPK pathway. The misguided myeloid dendritic cell (DC) model proposes that high-risk, multisystem, risk-organ-positive (MS-RO+) LCH results from driver mutation in a bone marrow (BM)-resident multipotent hematopoietic progenitor, while low-risk, MS-RO- and single-system LCH would result from driver mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.